Table 1.
Clinical Characteristics of Healthcare Resource Users and Non-Users.
| Total (n = 467) | HRU (n = 305) |
No HRU (n = 163) |
Odds Ratio | 95% Confidence Interval | P Value | ||
|---|---|---|---|---|---|---|---|
| Demographics and disease characteristics | |||||||
| Age (mean years ± SEM) | 44.0 ± 0.7 | 43.7 ± 0.9 | 44.7 ± 1.3 | 0.493 | |||
| Gender [female (%)] | 247 (52.7%) | 160 (52.5%) | 87 (53.4%) | 1.03 | 0.70 | 1.51 | 0.878 |
| IBD Subtype (CD/UC/IC) | 315/142/11 | 211 / 87 / 7 | 104 / 55 / 4 | 1.28 | 0.85 | 1.94 | 0.236 |
| Moderate to Severe inflammation (%) (on endoscopic evaluation) | 174 (37.1%) | 115 (37.7%) | 59 (36.2%) | 1.08 | 0.73 | 1.60 | 0.708 |
| Disease complication (%) | 192 (40.9%) | 134 (43.9%) | 58 (35.6%) | 1.42 | 0.96 | 2.10 | 0.081 |
| Medication use | |||||||
| Biologic use (%) | 225 (48.0%) | 154 (50.5%) | 71 (43.6%) | 1.32 | 0.90 | 1.94 | 0.153 |
| Mesalamine use (%) | 99 (21.1%) | 51 (16.7%) | 48 (29.4%) | 0.48 | 0.31 | 0.76 | 0.001 |
| Immunomodulator use (%) | 123 (26.2%) | 82 (26.9%) | 41 (25.2%) | 1.09 | 0.71 | 1.69 | 0.685 |
| Corticosteroid use (%) | 67 (14.3%) | 52 (17.0%) | 15 (9.2%) | 2.03 | 1.10 | 3.73 | 0.023 |
| Antidepressant or Anxiolytic (%) | 119 (25.4%) | 80 (26.2%) | 39 (23.9%) | 1.13 | 0.73 | 1.76 | 0.586 |
| NSAID use (%) | 85 (18.1%) | 47 (15.4%) | 38 (23.3%) | 0.60 | 0.37 | 0.97 | 0.036 |
| Opioid use (%) | 52 (11.1%) | 41 (13.4%) | 11 (6.7%) | 2.15 | 1.07 | 4.30 | 0.031 |
| Tobacco use (%) | 44 (9.4%) | 35 (11.5%) | 9 (5.5%) | 2.10 | 0.97 | 4.55 | 0.061 |
| Symptoms | |||||||
| Extra-intestinal manifestations (%) | 151 (32.2%) | 104 (34.1%) | 47 (28.8%) | 1.28 | 0.85 | 1.95 | 0.239 |
| Arthralgia (%) | 117 (24.9%) | 84 (27.5%) | 33 (20.2%) | 1.50 | 0.95 | 2.37 | 0.084 |
| Dermatopathies (%) | 41 (8.7%) | 29 (9.5%) | 12 (7.4%) | 1.35 | 0.67 | 2.72 | 0.405 |
| Anxiety or Depression (%) | 236 (50.3%) | 166 (54.4%) | 70 (42.9%) | 1.59 | 1.08 | 2.33 | 0.018 |
| Fatigue (%) | 392 (83.6%) | 266 (87.2%) | 126 (77.3%) | 2.00 | 1.22 | 3.29 | 0.006 |
| Fecal urgency (%) | 320 (68.2%) | 212 (69.5%) | 108 (66.3%) | 1.16 | 0.77 | 1.74 | 0.471 |
| Abdominal pain (%) | 298 (63.5%) | 216 (70.8%) | 82 (50.3%) | 2.40 | 1.62 | 3.55 | < 0.001 |
| Tenesmus (%) | 228 (48.6%) | 155 (50.8%) | 73 (44.8%) | 1.27 | 0.87 | 1.87 | 0.214 |
| Gas (%) | 220 (46.9%) | 147 (48.2%) | 73 (44.8%) | 1.15 | 0.78 | 1.68 | 0.481 |
| Diarrhea (%) | 182 (38.8%) | 118 (38.7%) | 64 (39.3%) | 0.98 | 0.66 | 1.44 | 0.903 |
| Rectal bleeding (%) | 170 (36.2%) | 117 (38.4%) | 53 (32.5%) | 1.29 | 0.87 | 1.93 | 0.211 |
HRU = Healthcare Resource Utilization, CD = Crohn’s disease, UC = ulcerative colitis, IC = indeterminate colitis. SEM = standard error measurement. Disease Complication = intra-abdominal stricturing, fistulae and/or abscess. IBD subtype analysis reports OR and CIs for CD vs. UC (excluding patients with IC).